Current Report Filing (8-k)
January 10 2022 - 4:25PM
Edgar (US Regulatory)
0001818331false00018183312022-01-102022-01-100001818331us-gaap:CommonClassAMember2022-01-102022-01-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 10, 2022
Sema4 Holdings Corp.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-39482
|
|
85-1966622
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
333 Ludlow Street, North Tower, 8th Floor
|
|
|
|
|
06902
|
|
Stamford,
|
Connecticut
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
(800) 298-6470
Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Class A common stock, par value $0.0001 per share
|
|
SMFR
|
|
The Nasdaq Global Select Market
|
|
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
|
|
SMFRW
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 7.01 Regulation FD Disclosure.
On January 10, 2022, Sema4 Holdings Corp. (the "Company") is furnishing as Exhibit 99.1 hereto a copy of the investor presentation to be used at the 40th Annual J.P. Morgan Healthcare Conference event.
The information in this current report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
|
|
|
|
Exhibit
Number
|
Description
|
|
99.1
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sema4 Holdings Corp.
|
|
|
|
|
|
Date:
|
January 10, 2022
|
By:
|
/s/ Eric Schadt
|
|
|
|
Name:
|
Eric Schadt
|
|
|
|
Title:
|
Chief Executive Officer
|
CM Life Sciences (NASDAQ:CMLFU)
Historical Stock Chart
From Mar 2024 to Apr 2024
CM Life Sciences (NASDAQ:CMLFU)
Historical Stock Chart
From Apr 2023 to Apr 2024
